SVB Leerink Lowers Viracta Therapeutics (NASDAQ:VIRX) to Market Perform

SVB Leerink cut shares of Viracta Therapeutics (NASDAQ:VIRX) from an outperform rating to a market perform rating in a research note published on Friday morning, Marketbeat reports. SVB Leerink currently has $3.00 target price on the stock, down from their previous target price of $5.00.

Other equities research analysts also recently issued reports about the company. Oppenheimer decreased their price objective on Viracta Therapeutics from $13.00 to $11.00 and set an outperform rating on the stock in a research report on Thursday, May 23rd. Royal Bank of Canada cut their target price on Viracta Therapeutics from $6.00 to $4.00 and set an outperform rating on the stock in a research report on Thursday, August 15th.

Viracta Therapeutics Price Performance

Shares of VIRX opened at $0.29 on Friday. The stock has a market capitalization of $11.50 million, a price-to-earnings ratio of -0.24 and a beta of 0.73. The business’s 50 day simple moving average is $0.51 and its 200-day simple moving average is $0.72. Viracta Therapeutics has a 1 year low of $0.28 and a 1 year high of $1.52.

About Viracta Therapeutics

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.